159,915 Shares in PROCEPT BioRobotics Corporation $PRCT Acquired by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon acquired 159,915 PROCEPT BioRobotics shares worth approximately $3.6 million, while institutional investors collectively own 89.46% of the company.
• Analyst sentiment is largely neutral: the stock has a consensus “Hold” rating and an average price target of $25.09, with several firms recently downgrading or lowering their targets.
• PROCEPT reported quarterly revenue of $94.5 million, up 19.3% year over year and above estimates, but posted an adjusted loss of $0.47 per share. The company also faces securities-litigation allegations related to weak handpiece sales and excess inventory.

Bank of New York Mellon Corp bought a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 159,915 shares of the company's stock, valued at approximately $3,611,000. Bank of New York Mellon Corp owned 0.28% of PROCEPT BioRobotics as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC lifted its stake in shares of PROCEPT BioRobotics by 7.3% in the first quarter. AQR Capital Management LLC now owns 18,892 shares of the company's stock worth $1,101,000 after buying an additional 1,286 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of PROCEPT BioRobotics by 9.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company's stock worth $8,923,000 after buying an additional 13,767 shares during the period. Intech Investment Management LLC grew its stake in PROCEPT BioRobotics by 54.4% in the 1st quarter. Intech Investment Management LLC now owns 28,389 shares of the company's stock valued at $1,654,000 after buying an additional 10,002 shares during the last quarter. Prudential Financial Inc. grew its stake in PROCEPT BioRobotics by 100.4% in the 2nd quarter. Prudential Financial Inc. now owns 6,815 shares of the company's stock valued at $393,000 after buying an additional 3,415 shares during the last quarter. Finally, State Street Corp lifted its position in PROCEPT BioRobotics by 6.9% during the 2nd quarter. State Street Corp now owns 1,269,110 shares of the company's stock worth $73,101,000 after acquiring an additional 81,849 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PRCT shares. Jefferies Financial Group restated a "hold" rating and set a $20.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. William Blair lowered PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Piper Sandler cut their price objective on PROCEPT BioRobotics from $35.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, August 5th. Citigroup downgraded PROCEPT BioRobotics to a "hold" rating in a research note on Thursday, July 2nd. Finally, UBS Group downgraded PROCEPT BioRobotics from a "buy" rating to a "neutral" rating and set a $20.00 target price for the company. in a research note on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $25.09.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $22.76 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The company has a 50-day simple moving average of $20.35 and a 200-day simple moving average of $23.66. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $41.51. The firm has a market capitalization of $1.30 billion, a P/E ratio of -11.73 and a beta of 0.91.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The firm had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. During the same period last year, the business earned ($0.35) earnings per share. The firm's quarterly revenue was up 19.3% compared to the same quarter last year. On average, equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current year.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: The stock’s increase suggests investors may be treating the latest announcements as repetitive legal notices rather than a new deterioration in the company’s business. The reports did not announce a judgment, settlement, regulatory penalty, or additional financial charge.
• Neutral Sentiment: Multiple firms—including Kaplan Fox class action deadline Kaplan Fox, Hagens Berman investor deadline Hagens Berman, and Rosen Law investor deadline Rosen Law—reminded investors that September 22, 2026 is the deadline to seek lead-plaintiff status. The proposed class covers purchases made from February 28, 2024, through February 25, 2026.
• Negative Sentiment: The lawsuit alleges that PROCEPT made misleading statements or failed to disclose repeated weakness in unit handpiece sales and excess customer inventory, allegedly caused in part by late-quarter bulk discounts. Law firms say these issues contributed to a substantial stock decline, including an approximately 18% drop cited in the filings. The allegations remain unproven, but continued litigation could increase costs, management distraction, and investor uncertainty. Hagens Berman securities fraud lawsuit

Insider Activity at PROCEPT BioRobotics

In other news, CEO Larry Wood acquired 23,900 shares of the stock in a transaction dated Friday, August 7th. The shares were acquired at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer owned 23,900 shares in the company, valued at approximately $498,315. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.00% of the company's stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.